https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/INCY/specialised-therapeutics-expands-partnership-with-incyte BiopharmaWatch en 2026-09-20T20:00:00.000Z Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia https://www.biopharmawatch.com/news/ASTS/ast-spacemobile-class-action-lawsuit BiopharmaWatch en 2026-09-20T14:00:00.000Z INVESTOR ALERT: AST SpaceMobile, Inc. (NASDAQ: ASTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit and Should Contact Kessler Topaz Meltzer & Check, LLP https://www.biopharmawatch.com/news/ORBS/eightco-holdings-nasdaq-orbs-meldt-totale-bezittingen-van-ongeveer-usd BiopharmaWatch en 2026-09-20T12:29:00.000Z Eightco Holdings (NASDAQ: ORBS) meldt totale bezittingen van ongeveer USD 380 miljoen, waaronder belangen in OpenAI en Beast Industries, meer dan 16.000 ETH en bijna 302 miljoen WLD-tokens https://www.biopharmawatch.com/news/CUE/cue-biopharma-positive-results-cue-221-phase-2-study BiopharmaWatch en 2026-09-20T10:00:00.000Z Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria https://www.biopharmawatch.com/news/CAH/class-action-lawsuit-cardinal-health-expenses BiopharmaWatch en 2026-09-19T22:32:00.000Z Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Cardinal Health 414, LLC, for Alleged Failure to Reimburse Employees' Business Expenses https://www.biopharmawatch.com/news/OSCR/oscar-health-thrive-capital-stock-distribution BiopharmaWatch en 2026-09-19T00:31:00.000Z Oscar Health Announces Thrive Capital’s Completion of Oscar Health Common Stock Distribution to its Limited Partners https://www.biopharmawatch.com/news/VIVI/tempramed-reports-record-sales-2026 BiopharmaWatch en 2026-09-18T20:45:00.000Z TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-nasdaq-notification-shareholders-equity BiopharmaWatch en 2026-09-18T20:45:00.000Z InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance